ArticleClinical case reports2025
Monoclonal Gammopathies of Clinical Significance-Scleromyxedema: A Case Report and Literature Review.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Monoclonal Gammopathies of Clinical Significance-Scleromyxedema: A Case Report and Literature Review.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scleromyxedema is an uncommon, chronic connective tissue disorder with an obscure etiology. It is distinguished by fibromyxoid skin lesions and elevated serum monoclonal immunoglobulin levels. The condition's rarity limits epidemiological data, making prevalence and incidence assessment difficult. Herein, we detail a clinical case of scleromyxedema, encompassing diagnosis and treatment, to augment medical understanding of this rare entity. The aim of this study is to delve into the complexities of diagnosing scleromyxedema, encompassing its diverse clinical presentations, with the goal of refining diagnostic acumen and expediting the identification process. This, in turn, mitigates the risks associated with diagnostic delays. Moreover, the imperative of instituting pertinent therapeutic measures is highlighted as a fundamental aspect of patient management, underscoring the significance of a tailored approach to treatment. Concurrently, this endeavor demands rigorous precision from clinical laboratory staff. The accurate provision of laboratory data is essential to prevent oversights and misinterpretations in diagnosing this rare condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.